Search results
Added:
1 month ago
Source:
Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
According to European Society of Cardiology (ESC) guidelines, a systematic search for diagnostic clues, or ‘red flags’ (RFs), is recommended in patients with hypertrophic cardiomyopathy (HCM) to help tailor disease management. A new study published in the European Heart Journal has investigated the prevalence and clinical significance of these RFs across different HCM phenotypes and clinical…
View more
Added:
1 month ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
A novel cardiac myosin agonist, danicamtiv, has shown favourable safety and efficacy signals in patients with dilated cardiomyopathy (DCM), particularly in those with specific genetic variants, according to results from a phase 2a open-label trial.¹ Precision therapies for DCM are currently lacking, despite its diverse clinical manifestations often linked to underlying genetic causes.²Danicamtiv…
View more
Added:
1 month ago
Source:
Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance…
View more